The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an ...

Black Diamond Therapeutics has deprioritized one of its two clinical-stage lung cancer contenders, jettisoned two executives ...

Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

A startup that aims to deliver a blood test to identify a biomarker linked with a specific subtype of autism—and then ...

Ceribell, the maker of a portable, brain-reading headset for emergency seizure care, aims to go public on the Nasdaq through ...

A phase 3 trial of Scholar Rock’s spinal muscular atrophy (SMA) candidate has hit its primary endpoint, sparking a 200%-plus ...

A year after the failure of an idiopathic pulmonary fibrosis candidate sent Galecto on a search for salvation, the ...

The FDA has placed Kezar Life Sciences’ lupus trial on hold after the biotech flagged four deaths during the phase 2b study.

AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...

Psyence Biomedical has walked away from its planned acquisition of fellow Canadian psilocybin-based biotech Clairvoyant ...

A minority of patients taking Ultragenyx Pharmaceutical’s Wilson disease gene therapy UX701 have come off standard-of-care ...